Overview

Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer

Status:
Completed
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
This Phase II randomized study is to determine the efficacy and toxicity of Nimotuzumab in combined with chemoradiotherapy for unresectable,local advanced squamous cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Cisplatin
Docetaxel
Nimotuzumab